Showing 1 - 6 results of 6 for search 'Monica Tani', query time: 0.04s Refine Results
  1. 1
    P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

    P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY by Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppa, Pauline Baumlin, Linda Lundberg, James Relf, Yuying Xie, Alessia Bottos, Kathryn Humphrey, Lorenzo Falchi

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

    Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study by Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Caterina Patti, Piero Maria Stefani, Antonio Cuneo, Gloria Margiotta Casaluci, Carlo Visco, Guido Gini, Fabrizio Pane, Francesco D’Alò, Debora Luzi, Maria Cantonetti, Samantha Pozzi, Gerardo Musuraca, Chiara Rosignoli, Annalisa Arcari, Sofya Kovalchuk, Monica Tani, Maria Chiara Tisi, Mario Petrini, Vittorio Stefoni, Pier Luigi Zinzani

    Published 2022-01-01
    Get full text
    Article
  3. 3
    A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

    A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial by Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, Roberto Passera, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Marco Ghislieri, Daniela Barbero, Ilaria Del Giudice, Monica Tani, Riccardo Moia, Stefano Volpetti, Maria Giuseppina Cabras, Nicola Di Renzo, Francesco Merli, Daniele Vallisa, Michele Spina, Anna Pascarella, Giancarlo Latte, Caterina Patti, Alberto Fabbri, Attilio Guarini, Umberto Vitolo, Olivier Hermine, Hanneke C Kluin-Nelemans, Sergio Cortelazzo, Martin Dreyling, Marco Ladetto

    Published 2021-12-01
    Get full text
    Article
  4. 4
    P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

    P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW... by Talha Munir, Mazyar Shadman, Tadeusz Robak, Jennifer R. Brown, Brad Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Simkovic, Anders Österberg, Luca Laurenti, Patricia Walker, Stephen Opat, Hanna Ciepluch, Richard Greil, Merit Hanna, Monica Tani, Marek Trneny, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Sophie De Guibert, Gayane Tumyan, Kamel Laribi, Jose Antonio Garcia Marco, Jianyong LI, Tian Tian, Vanitha Ramakrishnan, Yu Liu, Andy Szeto, Jason Paik, Aileen Cohen, Constantine Tam, Wojciech Jurczak

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

    Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LL... by Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, Gianluigi Reda, Livio Trentin, Paolo Sportoletti, Monia Marchetti, Daniela Pietrasanta, Roberto Marasca, Gianluca Gaidano, Marta Coscia, Caterina Stelitano, Donato Mannina, Nicola Di Renzo, Fiorella Ilariucci, Anna Marina Liberati, Lorella Orsucci, Francesca Re, Monica Tani, Gerardo Musuraca, Daniela Gottardi, Pier Luigi Zinzani, Alessandro Gozzetti, Annalia Molinari, Massimo Gentile, Annalisa Chiarenza, Luca Laurenti, Marzia Varettoni, Adalberto Ibatici, Roberta Murru, Valeria Ruocco, Ilaria Del Giudice, Maria Stefania De Propris, Irene Della Starza, Sara Raponi, Mauro Nanni, Paola Fazi, Antonino Neri, Anna Guarini, Gian Matteo Rigolin, Alfonso Piciocchi, Antonio Cuneo, Robin Foà

    Published 2021-12-01
    Get full text
    Article
  6. 6
    Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

    Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study by Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Luca Laurenti, Massimo Massaia, Ramona Cassin, Marta Coscia, Caterina Patti, Elsa Pennese, Agostino Tafuri, Annalisa Chiarenza, Piero Galieni, Omar Perbellini, Carmine Selleri, Catello Califano, Felicetto Ferrara, Antonio Cuneo, Marco Murineddu, Gaetano Palumbo, Ilaria Scortechini, Alessandra Tedeschi, Livio Trentin, Marzia Varettoni, Fabrizio Pane, Anna Marina Liberati, Francesco Merli, Lucia Morello, Gerardo Musuraca, Monica Tani, Adalberto Ibatici, Giulia Regazzoni, Michele Di Candia, Maria Palma, Danilo Arienti, Stefano Molica

    Published 2024-03-01
    Get full text
    Article

Search Tools: